Pembrolizumab Clinical Use and Safety Monitoring

Authored by Eric Kowalchyk, published on 2026-10-16 19:10:18.0

The algorithm is broadly aligned with the current pembrolizumab label and ASCO immune-related adverse-event guidance. It appropriately addresses indication verification, approved dosing, baseline and ongoing monitoring, grade-based toxicity management, infusion reactions, and avoidance of dose reduction. It should function as an overview rather than replace indication-specific protocols or organ-specific irAE pathways.

  1. Confirm Indication, Biomarker Eligibility, Treatment Setting, and Regimen
    The current prescribing information defines approved indications, required biomarkers, treatment settings, companion diagnostics, and combination regimens.
    • Obtain CBC, CMP, Thyroid Tests, Pregnancy Test; Teach irAE Reporting
      The label requires baseline and periodic hepatic, renal, and thyroid assessment and pregnancy verification when applicable; ASCO supports baseline laboratory evaluation and patient education. CBC requirements may additionally depend on the cancer and combination regimen.
      • Autoimmune Disease, Transplant, Pregnancy, Prior Severe irAE, or High-Risk Context?
        • Adult or Pediatric Patient?
          • Adults: Give 200 mg Q3W or 400 mg Q6W
            These are the labeled intravenous adult schedules, subject to indication-specific duration and combination instructions.
            • Confirm Indication-Specific Duration and Combination-Agent Timing
              • Before Each Dose, Review Symptoms and Due Safety Laboratories
                Ongoing symptom surveillance and periodic liver, renal, and thyroid testing are central to early irAE detection; additional tests depend on symptoms and regimen.
                • Suspected irAE?
                  • Other Clinically Significant Toxicity Present?
                    • Infuse IV Over 30 Minutes Through 0.2–5-Micron Filter
                      The administration method exactly reflects current intravenous pembrolizumab labeling.
                      • Infusion-Related Reaction?
                        • Perform Periodic Safety Review and Indication-Specific Response Imaging
                        • Grade 1–2 Reaction: Interrupt or Slow Infusion; Treat Symptoms
                          • Perform Periodic Safety Review and Indication-Specific Response Imaging
                        • Grade 3–4 Reaction: Stop Infusion and Permanently Discontinue
                    • Manage Non-irAE Toxicity Per Causative-Agent or Condition Pathway
                  • Exclude Infection, Progression, and Other Causes; Grade Toxicity
                    Both the label and ASCO recommend evaluating alternative etiologies, including infection and malignancy-related causes, before assigning an immune-mediated diagnosis and management grade.
                    • What Is the irAE Severity?
                      • Grade 1 Non–High-Risk irAE: Continue With Close Monitoring
                        • Infuse IV Over 30 Minutes Through 0.2–5-Micron Filter
                          The administration method exactly reflects current intravenous pembrolizumab labeling.
                          • Infusion-Related Reaction?
                            • Perform Periodic Safety Review and Indication-Specific Response Imaging
                            • Grade 1–2 Reaction: Interrupt or Slow Infusion; Treat Symptoms
                              • Perform Periodic Safety Review and Indication-Specific Response Imaging
                            • Grade 3–4 Reaction: Stop Infusion and Permanently Discontinue
                      • Grade 2 irAE: Withhold; Start Prednisone 0.5–1 mg/kg/day if Indicated
                        • Grade 0–1 and Prednisone ≤10 mg/day Within 12 Weeks, With Toxicity-Specific Resumption Criteria Met?
                          • Taper Corticosteroids Over ≥4 Weeks; Resume Only When Eligible
                            A slow taper reduces relapse risk, although some organ toxicities require longer tapers. Resumption should occur only after label and organ-specific recovery criteria are satisfied.
                            • Infuse IV Over 30 Minutes Through 0.2–5-Micron Filter
                              The administration method exactly reflects current intravenous pembrolizumab labeling.
                              • Infusion-Related Reaction?
                                • Perform Periodic Safety Review and Indication-Specific Response Imaging
                                • Grade 1–2 Reaction: Interrupt or Slow Infusion; Treat Symptoms
                                  • Perform Periodic Safety Review and Indication-Specific Response Imaging
                                • Grade 3–4 Reaction: Stop Infusion and Permanently Discontinue
                          • No Improvement or Failed Taper: Escalate Immunosuppression; Discontinue per Label
                      • Grade 3 irAE: Hold; Start Prednisone 1–2 mg/kg/day and Urgent Specialty Care
                        Grade 3 irAEs generally require treatment interruption, high-dose systemic corticosteroids, urgent evaluation, and organ-specialist involvement; hospitalization or intravenous methylprednisolone may be required.
                        • Grade 0–1 and Prednisone ≤10 mg/day Within 12 Weeks, With Toxicity-Specific Resumption Criteria Met?
                          • Taper Corticosteroids Over ≥4 Weeks; Resume Only When Eligible
                            A slow taper reduces relapse risk, although some organ toxicities require longer tapers. Resumption should occur only after label and organ-specific recovery criteria are satisfied.
                            • Infuse IV Over 30 Minutes Through 0.2–5-Micron Filter
                              The administration method exactly reflects current intravenous pembrolizumab labeling.
                              • Infusion-Related Reaction?
                                • Perform Periodic Safety Review and Indication-Specific Response Imaging
                                • Grade 1–2 Reaction: Interrupt or Slow Infusion; Treat Symptoms
                                  • Perform Periodic Safety Review and Indication-Specific Response Imaging
                                • Grade 3–4 Reaction: Stop Infusion and Permanently Discontinue
                          • No Improvement or Failed Taper: Escalate Immunosuppression; Discontinue per Label
                      • Grade 4, Recurrent Grade 3, or Label-Defined High-Risk Toxicity: Permanently Discontinue
                        The label supports permanent discontinuation for life-threatening toxicity, recurrent severe toxicity requiring systemic immunosuppression, and specified high-risk toxicities. Controlled endocrinopathies and certain hematologic situations are important exceptions.
          • Pediatrics: Give 2 mg/kg Q3W, Maximum 200 mg
            The dose is label-concordant for approved pediatric indications, but pembrolizumab is not universally indicated for all pediatric cancers or ages.
            • Confirm Indication-Specific Duration and Combination-Agent Timing
              • Before Each Dose, Review Symptoms and Due Safety Laboratories
                Ongoing symptom surveillance and periodic liver, renal, and thyroid testing are central to early irAE detection; additional tests depend on symptoms and regimen.
                • Suspected irAE?
                  • Other Clinically Significant Toxicity Present?
                    • Infuse IV Over 30 Minutes Through 0.2–5-Micron Filter
                      The administration method exactly reflects current intravenous pembrolizumab labeling.
                      • Infusion-Related Reaction?
                        • Perform Periodic Safety Review and Indication-Specific Response Imaging
                        • Grade 1–2 Reaction: Interrupt or Slow Infusion; Treat Symptoms
                          • Perform Periodic Safety Review and Indication-Specific Response Imaging
                        • Grade 3–4 Reaction: Stop Infusion and Permanently Discontinue
                    • Manage Non-irAE Toxicity Per Causative-Agent or Condition Pathway
                  • Exclude Infection, Progression, and Other Causes; Grade Toxicity
                    Both the label and ASCO recommend evaluating alternative etiologies, including infection and malignancy-related causes, before assigning an immune-mediated diagnosis and management grade.
                    • What Is the irAE Severity?
                      • Grade 1 Non–High-Risk irAE: Continue With Close Monitoring
                        • Infuse IV Over 30 Minutes Through 0.2–5-Micron Filter
                          The administration method exactly reflects current intravenous pembrolizumab labeling.
                          • Infusion-Related Reaction?
                            • Perform Periodic Safety Review and Indication-Specific Response Imaging
                            • Grade 1–2 Reaction: Interrupt or Slow Infusion; Treat Symptoms
                              • Perform Periodic Safety Review and Indication-Specific Response Imaging
                            • Grade 3–4 Reaction: Stop Infusion and Permanently Discontinue
                      • Grade 2 irAE: Withhold; Start Prednisone 0.5–1 mg/kg/day if Indicated
                        • Grade 0–1 and Prednisone ≤10 mg/day Within 12 Weeks, With Toxicity-Specific Resumption Criteria Met?
                          • Taper Corticosteroids Over ≥4 Weeks; Resume Only When Eligible
                            A slow taper reduces relapse risk, although some organ toxicities require longer tapers. Resumption should occur only after label and organ-specific recovery criteria are satisfied.
                            • Infuse IV Over 30 Minutes Through 0.2–5-Micron Filter
                              The administration method exactly reflects current intravenous pembrolizumab labeling.
                              • Infusion-Related Reaction?
                                • Perform Periodic Safety Review and Indication-Specific Response Imaging
                                • Grade 1–2 Reaction: Interrupt or Slow Infusion; Treat Symptoms
                                  • Perform Periodic Safety Review and Indication-Specific Response Imaging
                                • Grade 3–4 Reaction: Stop Infusion and Permanently Discontinue
                          • No Improvement or Failed Taper: Escalate Immunosuppression; Discontinue per Label
                      • Grade 3 irAE: Hold; Start Prednisone 1–2 mg/kg/day and Urgent Specialty Care
                        Grade 3 irAEs generally require treatment interruption, high-dose systemic corticosteroids, urgent evaluation, and organ-specialist involvement; hospitalization or intravenous methylprednisolone may be required.
                        • Grade 0–1 and Prednisone ≤10 mg/day Within 12 Weeks, With Toxicity-Specific Resumption Criteria Met?
                          • Taper Corticosteroids Over ≥4 Weeks; Resume Only When Eligible
                            A slow taper reduces relapse risk, although some organ toxicities require longer tapers. Resumption should occur only after label and organ-specific recovery criteria are satisfied.
                            • Infuse IV Over 30 Minutes Through 0.2–5-Micron Filter
                              The administration method exactly reflects current intravenous pembrolizumab labeling.
                              • Infusion-Related Reaction?
                                • Perform Periodic Safety Review and Indication-Specific Response Imaging
                                • Grade 1–2 Reaction: Interrupt or Slow Infusion; Treat Symptoms
                                  • Perform Periodic Safety Review and Indication-Specific Response Imaging
                                • Grade 3–4 Reaction: Stop Infusion and Permanently Discontinue
                          • No Improvement or Failed Taper: Escalate Immunosuppression; Discontinue per Label
                      • Grade 4, Recurrent Grade 3, or Label-Defined High-Risk Toxicity: Permanently Discontinue
                        The label supports permanent discontinuation for life-threatening toxicity, recurrent severe toxicity requiring systemic immunosuppression, and specified high-risk toxicities. Controlled endocrinopathies and certain hematologic situations are important exceptions.
        • Benefit Outweighs Risk After Multidisciplinary Review?
          • Adult or Pediatric Patient?
            • Adults: Give 200 mg Q3W or 400 mg Q6W
              These are the labeled intravenous adult schedules, subject to indication-specific duration and combination instructions.
              • Confirm Indication-Specific Duration and Combination-Agent Timing
                • Before Each Dose, Review Symptoms and Due Safety Laboratories
                  Ongoing symptom surveillance and periodic liver, renal, and thyroid testing are central to early irAE detection; additional tests depend on symptoms and regimen.
                  • Suspected irAE?
                    • Other Clinically Significant Toxicity Present?
                      • Infuse IV Over 30 Minutes Through 0.2–5-Micron Filter
                        The administration method exactly reflects current intravenous pembrolizumab labeling.
                        • Infusion-Related Reaction?
                          • Perform Periodic Safety Review and Indication-Specific Response Imaging
                          • Grade 1–2 Reaction: Interrupt or Slow Infusion; Treat Symptoms
                            • Perform Periodic Safety Review and Indication-Specific Response Imaging
                          • Grade 3–4 Reaction: Stop Infusion and Permanently Discontinue
                      • Manage Non-irAE Toxicity Per Causative-Agent or Condition Pathway
                    • Exclude Infection, Progression, and Other Causes; Grade Toxicity
                      Both the label and ASCO recommend evaluating alternative etiologies, including infection and malignancy-related causes, before assigning an immune-mediated diagnosis and management grade.
                      • What Is the irAE Severity?
                        • Grade 1 Non–High-Risk irAE: Continue With Close Monitoring
                          • Infuse IV Over 30 Minutes Through 0.2–5-Micron Filter
                            The administration method exactly reflects current intravenous pembrolizumab labeling.
                            • Infusion-Related Reaction?
                              • Perform Periodic Safety Review and Indication-Specific Response Imaging
                              • Grade 1–2 Reaction: Interrupt or Slow Infusion; Treat Symptoms
                                • Perform Periodic Safety Review and Indication-Specific Response Imaging
                              • Grade 3–4 Reaction: Stop Infusion and Permanently Discontinue
                        • Grade 2 irAE: Withhold; Start Prednisone 0.5–1 mg/kg/day if Indicated
                          • Grade 0–1 and Prednisone ≤10 mg/day Within 12 Weeks, With Toxicity-Specific Resumption Criteria Met?
                            • Taper Corticosteroids Over ≥4 Weeks; Resume Only When Eligible
                              A slow taper reduces relapse risk, although some organ toxicities require longer tapers. Resumption should occur only after label and organ-specific recovery criteria are satisfied.
                              • Infuse IV Over 30 Minutes Through 0.2–5-Micron Filter
                                The administration method exactly reflects current intravenous pembrolizumab labeling.
                                • Infusion-Related Reaction?
                                  • Perform Periodic Safety Review and Indication-Specific Response Imaging
                                  • Grade 1–2 Reaction: Interrupt or Slow Infusion; Treat Symptoms
                                    • Perform Periodic Safety Review and Indication-Specific Response Imaging
                                  • Grade 3–4 Reaction: Stop Infusion and Permanently Discontinue
                            • No Improvement or Failed Taper: Escalate Immunosuppression; Discontinue per Label
                        • Grade 3 irAE: Hold; Start Prednisone 1–2 mg/kg/day and Urgent Specialty Care
                          Grade 3 irAEs generally require treatment interruption, high-dose systemic corticosteroids, urgent evaluation, and organ-specialist involvement; hospitalization or intravenous methylprednisolone may be required.
                          • Grade 0–1 and Prednisone ≤10 mg/day Within 12 Weeks, With Toxicity-Specific Resumption Criteria Met?
                            • Taper Corticosteroids Over ≥4 Weeks; Resume Only When Eligible
                              A slow taper reduces relapse risk, although some organ toxicities require longer tapers. Resumption should occur only after label and organ-specific recovery criteria are satisfied.
                              • Infuse IV Over 30 Minutes Through 0.2–5-Micron Filter
                                The administration method exactly reflects current intravenous pembrolizumab labeling.
                                • Infusion-Related Reaction?
                                  • Perform Periodic Safety Review and Indication-Specific Response Imaging
                                  • Grade 1–2 Reaction: Interrupt or Slow Infusion; Treat Symptoms
                                    • Perform Periodic Safety Review and Indication-Specific Response Imaging
                                  • Grade 3–4 Reaction: Stop Infusion and Permanently Discontinue
                            • No Improvement or Failed Taper: Escalate Immunosuppression; Discontinue per Label
                        • Grade 4, Recurrent Grade 3, or Label-Defined High-Risk Toxicity: Permanently Discontinue
                          The label supports permanent discontinuation for life-threatening toxicity, recurrent severe toxicity requiring systemic immunosuppression, and specified high-risk toxicities. Controlled endocrinopathies and certain hematologic situations are important exceptions.
            • Pediatrics: Give 2 mg/kg Q3W, Maximum 200 mg
              The dose is label-concordant for approved pediatric indications, but pembrolizumab is not universally indicated for all pediatric cancers or ages.
              • Confirm Indication-Specific Duration and Combination-Agent Timing
                • Before Each Dose, Review Symptoms and Due Safety Laboratories
                  Ongoing symptom surveillance and periodic liver, renal, and thyroid testing are central to early irAE detection; additional tests depend on symptoms and regimen.
                  • Suspected irAE?
                    • Other Clinically Significant Toxicity Present?
                      • Infuse IV Over 30 Minutes Through 0.2–5-Micron Filter
                        The administration method exactly reflects current intravenous pembrolizumab labeling.
                        • Infusion-Related Reaction?
                          • Perform Periodic Safety Review and Indication-Specific Response Imaging
                          • Grade 1–2 Reaction: Interrupt or Slow Infusion; Treat Symptoms
                            • Perform Periodic Safety Review and Indication-Specific Response Imaging
                          • Grade 3–4 Reaction: Stop Infusion and Permanently Discontinue
                      • Manage Non-irAE Toxicity Per Causative-Agent or Condition Pathway
                    • Exclude Infection, Progression, and Other Causes; Grade Toxicity
                      Both the label and ASCO recommend evaluating alternative etiologies, including infection and malignancy-related causes, before assigning an immune-mediated diagnosis and management grade.
                      • What Is the irAE Severity?
                        • Grade 1 Non–High-Risk irAE: Continue With Close Monitoring
                          • Infuse IV Over 30 Minutes Through 0.2–5-Micron Filter
                            The administration method exactly reflects current intravenous pembrolizumab labeling.
                            • Infusion-Related Reaction?
                              • Perform Periodic Safety Review and Indication-Specific Response Imaging
                              • Grade 1–2 Reaction: Interrupt or Slow Infusion; Treat Symptoms
                                • Perform Periodic Safety Review and Indication-Specific Response Imaging
                              • Grade 3–4 Reaction: Stop Infusion and Permanently Discontinue
                        • Grade 2 irAE: Withhold; Start Prednisone 0.5–1 mg/kg/day if Indicated
                          • Grade 0–1 and Prednisone ≤10 mg/day Within 12 Weeks, With Toxicity-Specific Resumption Criteria Met?
                            • Taper Corticosteroids Over ≥4 Weeks; Resume Only When Eligible
                              A slow taper reduces relapse risk, although some organ toxicities require longer tapers. Resumption should occur only after label and organ-specific recovery criteria are satisfied.
                              • Infuse IV Over 30 Minutes Through 0.2–5-Micron Filter
                                The administration method exactly reflects current intravenous pembrolizumab labeling.
                                • Infusion-Related Reaction?
                                  • Perform Periodic Safety Review and Indication-Specific Response Imaging
                                  • Grade 1–2 Reaction: Interrupt or Slow Infusion; Treat Symptoms
                                    • Perform Periodic Safety Review and Indication-Specific Response Imaging
                                  • Grade 3–4 Reaction: Stop Infusion and Permanently Discontinue
                            • No Improvement or Failed Taper: Escalate Immunosuppression; Discontinue per Label
                        • Grade 3 irAE: Hold; Start Prednisone 1–2 mg/kg/day and Urgent Specialty Care
                          Grade 3 irAEs generally require treatment interruption, high-dose systemic corticosteroids, urgent evaluation, and organ-specialist involvement; hospitalization or intravenous methylprednisolone may be required.
                          • Grade 0–1 and Prednisone ≤10 mg/day Within 12 Weeks, With Toxicity-Specific Resumption Criteria Met?
                            • Taper Corticosteroids Over ≥4 Weeks; Resume Only When Eligible
                              A slow taper reduces relapse risk, although some organ toxicities require longer tapers. Resumption should occur only after label and organ-specific recovery criteria are satisfied.
                              • Infuse IV Over 30 Minutes Through 0.2–5-Micron Filter
                                The administration method exactly reflects current intravenous pembrolizumab labeling.
                                • Infusion-Related Reaction?
                                  • Perform Periodic Safety Review and Indication-Specific Response Imaging
                                  • Grade 1–2 Reaction: Interrupt or Slow Infusion; Treat Symptoms
                                    • Perform Periodic Safety Review and Indication-Specific Response Imaging
                                  • Grade 3–4 Reaction: Stop Infusion and Permanently Discontinue
                            • No Improvement or Failed Taper: Escalate Immunosuppression; Discontinue per Label
                        • Grade 4, Recurrent Grade 3, or Label-Defined High-Risk Toxicity: Permanently Discontinue
                          The label supports permanent discontinuation for life-threatening toxicity, recurrent severe toxicity requiring systemic immunosuppression, and specified high-risk toxicities. Controlled endocrinopathies and certain hematologic situations are important exceptions.
          • Defer Pembrolizumab and Select an Alternative Pathway
  2. Do Not Dose-Reduce Pembrolizumab; Hold or Discontinue for Toxicity
tosprivacyKeytruda Full Prescribing Information